The Predictive Individual Effect for Survival Data
Beat Neuenschwander, Satrajit Roychoudhury, Simon Wandel, Kannan, Natarajan, Emmanuel Zuber

TL;DR
This paper introduces the predictive individual effect, a patient-centric measure for survival data that provides intuitive insights into clinical benefit, especially in complex oncology trials with non-constant treatment effects.
Contribution
The paper proposes the predictive individual effect as a new, interpretable measure for survival analysis applicable to various hazard scenarios, enhancing clinical communication.
Findings
Applicable to proportional and non-proportional hazards
Provides insights beyond p-values and hazard ratios
Facilitates clearer communication of clinical benefits
Abstract
The call for patient-focused drug development is loud and clear, as expressed in the 21st Century Cures Act and in recent guidelines and initiatives of regulatory agencies. Among the factors contributing to modernized drug development and improved health-care activities are easily interpretable measures of clinical benefit. In addition, special care is needed for cancer trials with time-to-event endpoints if the treatment effect is not constant over time. We propose the predictive individual effect which is a patient-centric and tangible measure of clinical benefit under a wide variety of scenarios. It can be obtained by standard predictive calculations under a rank preservation assumption that has been used previously in trials with treatment switching. We discuss four recent Oncology trials that cover situations with proportional as well as non-proportional hazards (delayed treatment…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Code & Models
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHealth Systems, Economic Evaluations, Quality of Life · Statistical Methods in Clinical Trials · Economic and Financial Impacts of Cancer
